💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Acarbose

CHEMBL404271 Phase 4 अनुमोदित Oligosaccharide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
645.6 g/mol
LogP
-8.8
Phase
4

Carbohydrate digestion in the small intestine is slowed by acarbose, which blocks the alpha-glucosidase enzymes that break complex sugars into absorbable monosaccharides. Because glucose then enters the circulation more gradually, the postprandial rise is blunted, and this luminal action means the drug does not itself provoke hypoglycaemia. It is used alongside diet and exercise in type 2 diabetes, chiefly to control after-meal glucose excursions. Undigested carbohydrate reaching the colon is fermented by bacteria, which accounts for the flatulence and bloating common early in treatment and for their tendency to lessen with time. The oligosaccharide has the formula C25H43NO18, near 645.6 g/mol.

An oral medication that slows the digestion of carbohydrates in the intestine by blocking enzymes that break down complex sugars, resulting in a more gradual rise in blood glucose after meals. It is used alongside diet and exercise to manage type 2 diabetes and lowers after-meal blood sugar spikes without causing low blood sugar on its own. Digestive side effects such as gas and bloating are common, especially early in treatment, and tend to improve over time.

आणविक भार

645.6000 g/mol

LogP

-8.80

TPSA

329.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

चिकित्सीय क्षेत्र

एंडोक्राइनोलॉजी टाइप 2 मधुमेह

क्रिया का तंत्र

An alpha-glucosidase inhibitor. Acarbose competitively and reversibly inhibits the brush-border alpha-glucosidases of the small intestine, and to a lesser extent pancreatic alpha-amylase, delaying the hydrolysis of starch and disaccharides into absorbable monosaccharides. Carbohydrate absorption is spread across a longer stretch of intestine, which blunts the post-meal rise in blood glucose without stimulating insulin secretion.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

An alpha-glucosidase inhibitor. Acarbose competitively and reversibly inhibits the brush-border alpha-glucosidases of the small intestine, and to a lesser extent pancreatic alpha-amylase, delaying the hydrolysis of starch and disaccharides into …

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H43NO18

                    

                    
                    

                        
HBD / HBA

                        
14 / 19

                    

                    
                    

                        
घूर्णनीय बंधन

                        
13

                    

                    
                    
                    

                        
भारी परमाणु

                        
44

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
An oral medication that slows the digestion of carbohydrates in the intestine by blocking enzymes that break down complex sugars, resulting in a more gradual rise in blood glucose after meals. It is used alongside diet and exercise to manage type 2 diabetes and lowers after-meal blood sugar spikes without causing low blood sugar on its own. Digestive side effects such as gas and bloating are common, especially early in treatment, and tend to improve over time.

                        

                    

                    

                    

                    
                    

                        
                        

                            
An alpha-glucosidase inhibitor. Acarbose competitively and reversibly inhibits the brush-border alpha-glucosidases of the small intestine, and to a lesser extent pancreatic alpha-amylase, delaying the hydrolysis of starch and disaccharides into absorbable monosaccharides. Carbohydrate absorption is spread across a longer stretch of intestine, which blunts the post-meal rise in blood glucose without stimulating insulin secretion.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Acarbose is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL404271.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9811704.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.